With the high prevalence of cancer in the Canadian population, the need for rapid, personalized diagnostic tests is as evident as ever. Nuclear imaging allows for the visualization and diagnosis of diseases, including cancer, by detecting the emitted radiation from an administered disease-seeking molecule that has been labeled with a radioactive isotope (radiotracer). Lead-203 (203Pb) is a radioactive isotope compatible with single-photon emission computed tomography (SPECT), a proven imaging technique.